SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999; 45: 577587.
  • 2
    Roesink JM, Moerland MA, Battermann JJ, Hordijk GJ, Terhaard CH. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2001; 51: 938946.
  • 3
    Roesink JM, Moerland MA, Hoekstra A, Van Rijk PP, Terhaard CH. Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose-volume response relationships. Int J Radiat Oncol Biol Phys. 2004; 58: 14511460.
  • 4
    Cheng VS, Downs J, Herbert D, Aramany M. The function of the parotid gland following radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 1981; 7: 253258.
  • 5
    Franzen L, Funegard U, Ericson T, Henriksson R. Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. Eur J Cancer. 1992; 28: 457462.
  • 6
    Mira JG, Wescott WB, Starcke EN, Shannon IL. Some factors influencing salivary function when treating with radiotherapy. Int J Radiat Oncol Biol Phys. 1981; 7: 535541.
  • 7
    Yuhas JM. Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3) doses. Radiat Res. 1970; 44: 621628.
  • 8
    Tanaka Y. Clinical experiences with a chemical radioprotector in tumour radiotherapy: WR-2721. In: SugharaT, editor. Modification of Radiosensitivity in Cancer Treatment. Tokyo: Academic Press; 1984: 6481.
  • 9
    Phillips TL, Kane L, Utley JF. Radioprotection of tumor and normal tissues by thiophosphate compounds. Cancer. 1973; 32: 528535.
  • 10
    Washburn LC, Rafter JJ, Hayes RL. Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat Res. 1976; 66: 100105.
  • 11
    Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials. 1980; 3: 211216.
  • 12
    Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol. 1999; 175( Suppl 4): 612.
  • 13
    Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2000; 46: 11051108.
  • 14
    McDonald S, Meyerowitz C, Smudzin T, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys. 1994; 29: 747754.
  • 15
    Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000; 18: 33393345.
  • 16
    Utley JF, Seaver N, Newton GL, Fahey RC. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys. 1984; 10: 15251528.
  • 17
    Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998; 9: 505509.
  • 18
    Sobin LH, Wittekind C. Head and neck tumors. In: SobinLH, WittekindC, editors. TNM Classification of Malignant Tumors. 6th ed. New York: John Wiley & Sons; 2002: 1947.
  • 19
    Wagner W, Radmard A, Schonekaes KG. A new administration schedule for amifostine as a radioprotector in cancer therapy. Anticancer Res. 1999; 19: 22812283.
  • 20
    Jellema AP, Doornaert P, Slotman BJ, Rene LC, Langendijk JA. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? Radiother Oncol. 2005; 77: 164171.
  • 21
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 13411346.
  • 22
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365376.
  • 23
    Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients.EORTC Quality of Life Study Group. Acta Oncol. 1994; 33: 879885.
  • 24
    Fayers P, Aaronson NK, Bjordal K, Sullivan M, on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Scoring Manual. Brussels: EORTC; 1995.
  • 25
    Wasserman T, Mackowiak JI, Brizel DM, et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys. 2000; 48: 10351039.
  • 26
    [No authors listed.] LENT SOMA tables. Radiother Oncol. 1995; 35: 1760.
  • 27
    National Institutes of Health. Common Toxicity Criteria for Adverse Events, version 3.0. Available at: http://ctep.info. nih.gov/CTC3/ctc.htm. Accessed April 1, 2003.
  • 28
    Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol. 2002; 63: 203211.
  • 29
    Liem IH, Olmos RA, Balm AJ, et al. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours. Eur J Nucl Med. 1996; 23: 14851490.
  • 30
    Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50: 695704.
  • 31
    Rades D, Fehlauer F, Bajrovic A, et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol. 2004; 70: 261264.
  • 32
    Boccia RV, Alster M, Houskamp E. Amifostine (Ethyol) given by rapid IV push is safe and tolerable. Proc Am Soc Clin Oncol. 2001; 20: 300b.
  • 33
    Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol. 2002; 29: 8083.
  • 34
    Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized Phase II study. J Clin Oncol. 2000; 18: 22262233.
  • 35
    Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol. 2000; 57: 113118.